Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Recurrence 1Neoplasm Metastasis 1Cholangiocarcinoma 1Carcinoma, Pancreatic Ductal 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

Gemcitabine 23Cisplatin 16pembrolizumab 6Fluorouracil 6pemigatinib 4Radiotherapy 3Oxaliplatin 3Leucovorin 3Drug Therapy 3infigratinib 2durvalumab 2ceritinib 2aldesleukin 2Radiosurgery 2Photochemotherapy 2Nivolumab 2Liver Transplantation 2Dexamethasone 2Cholangiopancreatography, Endoscopic Retrograde 2Carboplatin 2Capecitabine 2trifluridine tipiracil drug combination 1tremelimumab 1trametinib 1spartalizumab 1seribantumab 1perfluoro-2,2,2',2'-tetramethyl-4,4'-bis(1,3-dioxolane) 1peginterferon alfa-2b 1pazopanib 1padeliporfin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Cholangiocarcinoma × PEGPH20 × Clear all
NCT03267940 2020-02-07

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Halozyme Therapeutics

Phase 1 Terminated
85 enrolled 17 charts
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡